Projected Growth of the Global Antidepressants Market to Reach $3.69 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the antidepressants market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Antidepressants Market By The End Of 2029?

The peptide and oligonucleotide cdmo market has seen substantial growth in recent years. Its valuation is predicted to expand from $2.16 billion in 2024 to $2.42 billion in 2025, achieving a compound annual growth rate (CAGR) of 11.8%. This historical market expansion can be ascribed to an increase in demand for therapeutic agents, innovations in synthesis and manufacturing, trends towards personalized medicine, adherence to regulatory guidelines, and an elevated focus on antiviral peptides and mRNA vaccines, which highlights the promise of oligonucleotides in vaccine creation.

The peptide and oligonucleotide CDMO market is projected for significant expansion in the coming years. This market is anticipated to reach a valuation of $3.69 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.2%. This projected growth is driven by factors such as the increasing need for personalized medicine, breakthroughs in biotechnology, broader application areas, a rise in outsourcing activities, and the escalating prevalence of chronic illnesses. Key trends anticipated during this period encompass the development of personalized therapies, continuous technological improvements, challenges related to quality control, a push for global market expansion, and enhanced cooperation between biopharmaceutical firms.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Which Business Drivers Are Underpinning The Growth Of The Antidepressants Market?

The increasing embrace of personalized medicine is anticipated to fuel expansion in the peptide and oligonucleotide CDMO markets in the future. This healthcare methodology involves customizing medical choices and therapies based on unique individual traits, including genetics, environmental factors, and lifestyle choices. Its rising acceptance stems from multiple elements like progress in genomic technologies, a deeper comprehension of disease processes at a molecular scale, and a need for more potent and precise therapeutic alternatives designed for patients’ specific genetic makeups and medical backgrounds. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are pivotal in personalized medicine, creating bespoke therapeutic peptides and oligonucleotides specifically for individual patient requirements. As an example, in February 2024, data from the Personalized Medicine Coalition, a UK-based entity advocating for personalized medicine, indicated that the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) sanctioned 16 novel personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the expanding use of personalized medicine is propelling the advancement of the peptide and oligonucleotide CDMO market.

What Are The Principal Segment Types In The Antidepressants Market?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

How Are Industry Trends Steering The Expansion Of The Antidepressants Market?

Leading companies in the peptide and oligonucleotide CDMO market are concentrating on forging strategic partnerships to enhance their service offerings, expand technological capabilities, and broaden their market reach. Peptide development and production partnerships signify collaborative agreements between two entities focused on developing and manufacturing peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), collaborated with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This alliance aims to utilize PolyPeptide’s cGMP manufacturing capacities and market access, alongside Numaferm’s expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is dedicated to jointly exploring the development of suitable peptide candidates with the objective of achieving more sustainable production of peptide-based APIs.

Which Companies Are Contributing Significantly To The Antidepressants Market Growth?

Major companies operating in the peptide and oligonucleotide CDMO market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Region Offers The Most Opportunity For Antidepressants Market Expansion?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

Browse Through More Reports Similar to the Global Antidepressants Market 2025, By The Business Research Company

Biologics Cdmo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Peptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Glycopeptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795